<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 58 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page57.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=58">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 58 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 58</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=58"><img src="../thumb/58.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Central Nervous System - 1.5.3                                                  2020-04 / 27
       Drug interactions: CNS effs.of other CNS depress. incl.alcoh.  Side effects: U/LRTI, eye/vir.infects., flu, UTI, cellulit., acarodermatit.,   & body temp.disregulat., incr plasma prolact.lev.& assoc. manifes-
       enhanc., incr.clear.with concom. carbamazepine/phenytoin/thiori-  onychomycos., cystit., gastro-enterit., infect., bld.dyscras., anaphy-  tat., psych.disords., somnol., CNS effs., dizzin., dos.depend.extrapy-
       dazine, act. of dopaminerg.antagon., decr.clear.with cemetidine, decr.  lact./ allerg. reacts., hypersens., incr.plasma prolact.lev., body temp.   ramid. sympts. incl. trem./rigidit./oculogyr.cris./akathis./ac. dyston./
       lorazepam clear., signific.incr.in quetiapine AUC with ketoconazole.  disregulat., water intox.due to polydips./ SIADH, diab.mellit.aggra-  hypokines., blurr.vis., refl.tachycard., hypo-/ hypertens., GI disturbs.,
       REDILANZ, Dr Reddy’s [P/S]    vat., ketoacidos., hyperglycaem., diab.coma, appet. chang., psych.   skin reacts., urin. incont., erect.-/ejaculat.-/orgasm.dysfunct., pria-
                                                                  pism, gynaecomast./galactorrh./menstr.cycle disturbs.& amenorrh.,
                                     disords.incl.mania/hypoman., CNS effs. incl.parkinsonism, dizzin.,
       Olanzapine.                   headache, extrapyramid. sympts.incl.trem.bradykines./ dyskines./   hyperglycaem./diab.mellit. excerbat.
       Indications: Psychot.disords., ac.mania in bipol. disord.  oculogyr.cris., akathis., ac.dyston., tard. dyskines., CVA incl.stroke/  Special precautions: High.mortalit.report.in elderly dement.pts.re-
       (S5) TABS, 42/2.6.5/0814, 0815, 0816  TIA, neurolept. malign. syndr., convuls., syncope, hypo-/paraesthes.,   ceiv.furosemide, avoid dehydrat. with concom.furosemide, diab.mel-
       715683-002: 2,5 mg, 28, R294,85  tard. dyston., Parkinson’s dis. aggrav./deterior., bal./ movem.disord.,   lit./ risk fact., fast.bld.gluc.test.advis.in pts. develop. hyperglycaem.
       715684-002: 5 mg, 28, R45625  involunt. musc.contract., mask. facies, cerebr.ischaem., blurr.vis.,   sympt., Parkinson.dis./dement.with Lewy bodies is at risk of NMS.&
       715685-002: 10 mg, 28, R593,25  conjunctivit., eye disords.incl.ocul.hyperaem./glauc./retin.art. oc-  incr.antipsychot. meds. sensitiv., concom.alcoh.& other central.act.
       Dosage: Admin.as once-a-day dos. Safety of dos. above 20 mg/  clus., vertigo, ear/chest/back/neck/ musculoskelet./ buttock pain,   meds., known CV dis.where grad.dos.titrat. recomm., consid.dos.re-
       day not eval.                 tinnit., card.disords. incl. AV block/tachycard./atrial fibrillat./pro-  duct.if hypotens.occurs, epilep., safety in pregn.& lactat.not est., ex-
       Init. 5-10 mg/day with target dos.of 10 mg/day within several days.   long. QT interv., orthostat.hypotens., hypertens., flush., nas./ resp./  cret.in breast milk, re-eval.ther if concom.fluoxetine/ paroxetine init./
       If indic. dos.adjustm.should occur at interv.of not less than 1 wk.  pulm.congest., cough, dyspn., pulm. embol., epistax., wheez., dys-  discont., safety & effic.in childr. und.15 yrs.for schizophren.not est.,
       Contraindications: Known narrow-angl. glauc. risk, safety in   phon., rales, hypervent., nas.oed., toothache, decr.salivat., anorex.,   ren.& liv. impairm., treatm.may suppress.S&S of TD poss. mask. un-
       pregn.& lactat.& childr.und.18 yrs. not est., concom.fluoxetine
       not recomm.                   intest.obstruct., pancreatit., dysphag., faecaloma, cheilit., aptyalism,   derly.process., prescrib.in manner to minim. TD risk, reg.assess.contin.
                                     jaund., skin reacts. incl.incr.pigment., seborrh.dermatit., alopec., ar-
                                                                  ther., discont. ther. if S&S of tard.dyskines., discont.all anti-psychot. &
       Side effects: Elev.prolact.lev., neurolept.malign. syndr., tard.dys-
       kines., diab.mellit.poss.assoc.with ketoacidos./hyperosmol.coma or   thralg., musc.weakn., joint swell./stiffn., rhabdomyolis., torticoll.,   not essent.meds.if NMS devel., consid. re-introduct.caref.& monit.aft.
                                                                  NMS recov.as NMS recurr. report., dos.-depend.plasma prolact.conc.
                                     urin./faec.incontin., micturit./ menstr./sex.funct.disturbs., polyur.,
       death, incr.QTc-interv., bld.dyscras., allerg.reacts.incl.anaphylact. re-
       act., rash, weight gain, incr.appetite, hyperglycaem., hypertriglyceri-  enures., dysur., pollakur., galactorrh., breast/chest discomf., erect.-/  poss. occur, preventat.hypo-oestrog.bone loss ther. in premenopaus.
                                     ejaculat.-/orgasm.dysfunct., priapism, gynaecomast., pyrex., periph.
                                                                  women with second.amenorrh.of &gt;6 mnths., warn pts.of poss.weight
       daem., CNS effs. incl.seiz., psych.disords., movem.disords., abnorm.
       gait, hyperton., articulat.impairm., extrapyrimid. effs., dyston., am-  oed./ coldn., asthen., fatig., malaise, thirst, chills, hypo-/hypertherm.,   gain, no caus. assoc. detect.with report benign pituit.adenomas., not
       blyop., blepharit., corn.les., chest pain, bradycard., tachycard., ECG   ECG abnorm., incr.bld.gluc./ prolact./ hepat.enzym., weight chang.,   for lact.intol.indiv., elderly, high incid.CVA & TIA in elderly with de-
       paramet. changes, ventric.arrhythm., orthostat.hypotens., hypotens.,   fall, hyperglycaem. somet.assoc.with ketoacidos./ hyperosmol. coma/  ment., limit.exper.in childr. und. 5 yrs.
       periph.oed., rhinit., cough, pharyngit., GI disturbs., pancreatit., trans.  death, benign pituat.adenoma.  Interactions: Carbamazepine /other hepat. enzyme induc.may decr.
       elev.liv.transaminase lev., hepatit., photosens., extremity-/back-/  Special precautions: Excret.in breast milk, advers. eff.observ.in   plasma lev., valproate/Li Tmax incr., slight decr.bioavail with topiramate,
       joint pain, premenstr.syndr., urin.incontin., priapism, fev., intent.injury.  neonat.expos.dur.last trimest. of pregn., ren./liv.impairm., tard.dys-  incr. plasma lev.with phenothiaz./TCA’s/some ß-block./ fluoxetine.&
       Special precautions: Elev.prolact.lev.persist. modestly dur.chron.  kines., elderly, epilep., concom.furosemide/alcoh./other centr. act.   paroxet., incr.AUC /decr.clear.with venlafaxine, cimetidine & raniti-
       admin.with incr.in mammary gland neoplasms in rodents thought to   meds., avoid dehydrat., excess.eat.as poss. weight gain, pre-exist.   dine incr. bioavailabil.
       be prolactin mediat., discont.if any clinic.NMS manifestat./high fev.  diab.mellit.exacerbat., incr. CV events /mortalit.risk in elderly pts.  RISPERDAL, Janssen Pharmaceutica [P/S]
       observ., consid.discont./dos.reduct.if tard. dyskines. S&S develop,   with dement., fast.bld.gluc.test advis.if hyperglycaem. devel., monit.  Risperidone
       tard.dyskines.risk incr.with long-term expos., monit.exist.diab.for   hyperglycaem. sympt.in pts.with diab. mellit.risk fact., tard.dyskines.  Indications: Ac.& chron.schizophren.psychos.& relat. psychos.
       worsen. gluc. contr., monit.pts.start.treatm.at risk of diab. for hy-  risk fact., cons. benef./ risk in Parkinson dis. as risk pts.devel.NMS   where posit.&/or negat.sympts.are promin.& effect.in main.clinic.
       perglycaem., fast.bld.gluc.if hyperglycaem. develops, some pts.  & incr. antipsychot. meds.sens., known CV dis. where grad. dos.ti-  improvem., alleviat. affect. sympts.assoc.with schizophren., mania in
       req.continuat.of anti-diabet. treatm.despite discont., hist.of seiz./  trat.recomm., consid.dos. reduct. if hypotens.occurs, concom.meds.  bipolar disord., conduct & disrupt.behav.disords. in childr. 5-12 yrs.with
       condits.assoc. with seiz./low.seiz.thresh., symptomat.prostat. en-  known to prolong. QT interv., Parkinson.S/E developm.poss. predict.   subaveg.intellect.funct./ ment. retard.where destruct.behav.is promin.
       largem., narr.angle glauc., paralyt.ileus & relat. condits., card.pts./  of TD & TD risk poss.incr.with treatm. durat. & tot. antipsychot. cu-  (S5) TABS, [P/S] 33/2.6.5/0111, 27/2.6.5/0235, 0236, 0237, 0238
       condits.predispos.to hypotens. due to orthostat.hypotens.risk, S&S   mulat.dos., treatm.may suppress. S&S of TD mask.underly.process.,   891523-008: 0,5 mg, 30, R401,71
       of hepat. impairm., pre-exist.condits.assoc.with limit.hepat. funct.  reg. assessm. for contin.ther., consid.ther.discont.if TD S&S appear,   828432-007: 1 mg, 30, R693,75
       reserve, concom.potent.hepatotox.meds., predispos.risk fact.in el-  discont.all anti-psychot./non-essent. meds. in NMS.sympt./treatm.&   801860-024: 2 mg, 30, R1 168,37
       derly, leucopen./ neutropen., meds.induc.bone marrow depress./   monit., consid.re-introd. caref.& monit.aft.NMS recov.as NMS recurr.   801879-035: 3 mg, 30, R1 708,28
       toxic., bone marrow depress., hypereosnophil. condits., myelopro-  report., prevent.hypo-oestrog.bone loss ther. in premenopaus.women   828440-018: 4 mg, 30, R2 275,69
       liferat.dis., plasma clear.high.in smokers, concom.centr.act.agents   with second. amenorrh. of &gt;6mnths., lact.intol.  (S5) ORAL SOL, [P/S] 30/2.6.5/0215. 1 mg/ml.
       & alcoh., concom. meds.known to incr.QTc interv./congenit. long QT   Drug interactions: Use with other concom. meds. not system.  823163-008: 30 ml, R732,50
       syndr./ CHF/card.hypertrophy/ hypokalaem. & hypomagnesaem.,   eval., may antagon.eff.of levodopa & other dopamine agonists,   Dosage: Schizophren: When switch.from other antipsychot. & if
       discont.if hepatit. diagnos., grad.discont.  carbamazepine & other hepat.enzyme induc.may decr. plasma lev.,   medic.appropr.discont.prev. treatm. grad.& if switch.from depot antip-
       Drug interactions: Fluoxetine incr.conc.& decr. clear., may an-  valproate Tmax incr., incr.plasma lev. with phenothiaz./TCA’s/some   sychot. init.Risperdal in place of next inj. Re-eval.need for contin.exist.
       tagon.effs.of levodopa & dopamine agonists, may enhanc.effs.  ß-block./ fluoxetine.& paroxet., venlafaxine decr.clear., cimetidine   anti-Parkinson.meds periodic. Dos. above 10 mg/ day have not been
       of cert.antihypertens., reduc.bioavail.with activat.charc., metabol.  & ranitidine incr.bioavailabil., Li-T max incr., poss.torsades de pointes   shown to be superior in effic.& may incr.incid.of S/E. Only consid. dos.
       poss. induc.by smok.& carbamazepine, CYP1A2 inhibit. reduc.clear.,   with meds.prolong. QT interv.  above 10 mg/day if benef.&gt;risk. Benzodiazep. may be add.if addit.se-
       CYP1A2 induc.incr.clear.      RISPACOR, Accord [P/S]       dat.is reqd. Safety & effic.in childr.und.15 yrs.for schizoprhen. not est.
       RISNIA, Cipla Medpro [P/S]    Risperidone                  Dos.above 6 mg/day assoc.with more extrapyramid. sympts.& other
                                                                                        st
       Risperidone                   Indications: Ac.& chron.schizophren.psychos.& relat. psychos.  adv.eff.& gen.not recomm. In some pts.partic.with 1  episod.of ac.
       Indications: Ac.& chron.schizophren.psychos.& relat.psychos.where   where posit.&/or negat.sympts.are promin., affect.sympts.assoc.  psychos. slow.titrat.phase & low.start.& maint. dos. may be appropr.
       posit.&/or negat.sympts.are promin., affect.sympts.assoc.with schizo-  with schizophren. alleviat., maint.clinic.improvem.where init.treatm.   Adults: Indiv. Admin.1-2xdly. All pts.to begin on 2 mg/day.which
       phren., maint.clinic. improvem. where init.treatm.reponse shown, ma-  reponse shown, behav.disturbs.in pts.with dement. when aggressiv-  may be incr.to 4 mg on 2nd day, indiv.furth.if reqd. Usual optim.dos.
       nia in pts.with bipolar disord.incl. disrupt. & aggress.behav., conduct   en./ activ.disturbs./psychot.sympts. are promin., conduct & disrupt.  is 4-8 mg/day. Max.tot.dly.dos: 16 mg/day. Elderly: Init.0,5 mg 2x dly.
       & disrupt. behav. disords.in childr. 5-12 yrs.with bel.aveg. intellect.   behav.disords.in childr. 5-12 yrs.with subaveg.intellect.funct./ment.   adjust. in 0,5 mg 2xdly.increm.to 1-2 mg 2x dly.
       funct. /ment.retard. where destruct.behav.is promin.  retard. where destruct. behav.is promin.  Bipolar mania: Exper.lack.in childr.und.18 yrs. Adults: Once dly dos.
       (S5) TABS, 42/2.6.5/0792, 0793, 0794, 0795  (S5) TABS, 42/2.6.5/0155, 0156, 0157, 0158  sched. Start with 2-3 mg. If indic.dos.adjustm.to be made at interv.of
       717996-001: 0,5 mg, 30, R119,16  714101-001: 0,5 mg, 30, R146,10  not less than 24 hrs.in 1 mg/day increm. Effic.demonstrat. over range
       717997-001: 1 mg, 30, R223,50  713967-001: 1 mg, 30, R223,50  of 1-6 mg/day. Eval.& justify cont use.
       717998-001: 2 mg, 30, R477,00  713966-001: 2 mg, 30, R477,00  Conduct & disrupt.behav.disords.in childr.5-12 yrs: &lt;50 kg:
       717999-001: 3 mg, 30, R714,90  713965-001: 3 mg, 30, R714,90  Init.0,01 mg/kg once dly. Indiv. adjust. in increm.of 0,01 mg/kg once
       Dosage: Schizophren: When switch.from other antipsychot.& if   Dosage: Schizophren: When switch.from other antipsychot.& if   dly.not more freq.than every other day if req. Recom.maint. dos:
       medic.appropr.discont.prev. treatm.grad. If switch from depot antip-  medic.appropr.discont prev. treatm. grad.& if switch.from depot an-  0,02-0,04 mg/kg once dly. Mean dos: 0,03 mg/ kg once dly. Eval.
       sychot.init. Risnia in place of next sched.inj. Re-eval.cont. exist. anti-  tipsychot. init. Rispacor in place of next sched. inj. Re-eval. cont.exist.   ongoing need reg.
       Parkinson meds.period.        anti-Parkinson meds.period. Adults: Admin. 1-2xdly. Init.2 mg/day.   (S5) RISPERDAL CONSTA PROLONG.RELEASE IMI SUSP, [P/S]
       Adults: Admin.1-2xdly. Init.2 mg/day.incr.to 4 mg on 2nd day, indiv.  May be incr.to 4 mg on 2nd day, indiv.furth.if reqd. Usual optim.dos:   37/2.6.5/0142, 0143, 0144
       furth.if reqd. Usual optim.dos.is 4-8 mg/ day. Dos.above 6 mg/day   4-8 mg/day. Dos.above 6 mg/day when admin.twice dly. assoc.with   Indications: Ac.& chron.schizophren., monother./ adjunct.ther.for
       when admin. twice dly.assoc.with more extrapyramid. sympts. &   more extrapyramid.sympts.& other adverse effs.& gen.not recomm.   maint.treatm.to prevent.manic episod.recurr.of bipol. I disord.in pts.
       other adverse effs.& gen.not recomm. Slow titrat.phase & low.start./  Slow.titr.phase & low. start./maint.dos.may be appropr.in some pts.   prev.respond.to oral antipsychot./other anti-manic treatm.
       maint.dos.may be appropr. in some pts.esp.with first ac.psychos. epi-  esp.with first ac.psychot.episod.  705474-001: 25 mg, Alaris Dev., R1 501,35
       sod. Dos.above 10 mg/day not shown to be superior in effic.& may   Dos.above 10 mg/day not shown to be superior in effic. & may incr.  705475-001: 37,5 mg, Alaris Dev., R2 101,88
       incr.incid.of S/E & only consid. aft.eval.risk vs.benef. Max.tot.dly.dos:   incid.of S/E & only consid.aft. eval. risk vs.benef. Max.tot.dly.dos:   705476-001: 50 mg, Alaris Dev., R2 702,43
       16 mg/day. Add benzodiazep.if addit.sedat reqd.  16 mg/day. Add benzodiazep.if addit.sedat.reqd. Elderly: Init. 0,5 mg   Dosage: Risperidone naive pts: Est.tolerabil. with oral risperidone
       Elderly: Init.0,5 mg 2x dly.adjust.indiv.in 0,5 mg 2xdly.increm.to   2x dly.adjust.in 0,5 mg 2xdly.increm.to 1-2 mg 2x dly.  bef.init.CONSTA treatm. Ensure suffic.antipsychot.treatm.coverage
                                                                               st
       1-2 mg 2x dly.                Behav.disturbs.in adult dement.pts: Init. 0,25 mg 2xdly. Indiv.if   dur.3 wk. lag period follow.1  inj. Admin.by deep IMI every 2wks.
       Bipol.mania: Admin.once dly start.with 2 or 3 mg/day. Dos.ad-  necess.in increm. of 0,25 mg 2xdly.not more freq.than every other   Adults incl.elderly: Recomm.dos: 25 mg IMI every 2 wks. Some
       justm.if indic.at interv.of not short.than 24 hrs & in increm.of 1 mg/  day if need. Optim. dos: 0,5 mg 2xdly.with some benefit.from dos. of   pts.benef.from high. dos.of 37,5 mg or 50 mg. Dos.above 50 mg not
       day. Effic.shown in dos range of 1-6 mg/day. Eval.& justif. cont.   upto 1 mg 2xdly. Once target.dos. reach. consid. once dly.dos. Eval.  stud.in bipol.disord. Upward.dos.adjust.not more freq. than every 4
       treatm.on ongoing basis.      cont.treatm.regul.           wks. Dos.high.than 50 mg every 2 wks not recomm. Refer to manu-
       Conduct & disrupt.behav.disords.in childr. 5-12 yrs: &lt;50 kg:   Conduct & disrupt.behav.disords.in childr. 5-12 yrs: &lt;50 kg: Init:   fact.prod .lit.for reconstit.
       Init.0,01 mg/kg once dly.recomm. Indiv. adjust.in increm.of 0,01 mg/  0,01 mg/kg once dly. Indiv. adjust. in increm.of 0,01 mg/kg once dly.not   Contraindications: Safety & effic.in childr.und. 18 yrs.not est. & no
       kg once dly.not more freq. than every other day if need. Recomm.   more freq.than every other day. Recomm.maint.dos: 0,02-0,04 mg/  studies for ren./hepat. impairm. for Consta presentat.est., safety &
       maint.dos: 0,02-0,04 mg/kg once dly. Mean aveg. dos: 0,03 mg/kg   kg once dly. Mean dos: 0,03 mg/kg once dly. Eval. ongo.need regul.  effic. of tabs.& oral sol. in childr.und.15 yrs.for schizophren. not est.,
       once dly. Eval.& justif.on ongoing basis. Oral sol.advis.for childr re-  Contraindications: Safety & effic.in childr.und. 5 yrs.for conduct &   safety & effic.of tabs.& oral sol. in childr.und.5 yrs.for conduct &
       quir.less than 0,5 mg/dos.or unable to swall.tabs.  other disrupt.behav.disords.not est., Lewy antibody dement.  other disrupt. behaviour disords.not est., lactat., safety in pregn. not
       Contraindications: Safety & effic.in childr.und. 5 yrs.for conduct   Side effects: Tard.dyskines.most.in elderly & esp. elderly fem., neu-  est., Parkinson’s, Lewy body dement., Consta: IV inj.& tabs: lact.intol.
       & other disrupt.behav.disords. not est., Parkinson’s dis.& Lewy body   rolept.malign.syndr., hyperglycaem. assoc.with ketoacidos./hyper-  Side effects: V.common: Parkinsonism., akathis., headache, URTI
       dement., safety in pregn.& lactat.not est., safety & effic.in childr.und.   osmol. coma/ death, CVA & TIA’s, orthostat.hypotens., seiz., weight   Common: Abnorm.ECG, bld. prolact. /bld.gluc./transaminas./body.
       15 yrs.for schizophren.not est., limit. exper.in bipol.mania in childr.&   gain, headache, fatig., angioed., allerg. reacts., decr.neutroph.&/  temp./bld. creatin. phosphokin.incr., weight incr./decr., AV block.,
       adolesc.young. than 18 yrs.   thrombocyte count, rhinit., water intoxicat.due to polydips./SIADH   tachycard., anaem., depress., insomn., anx., dizzin., somnol., sedat.,</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page57.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page53.html">53</a>&nbsp;&nbsp;&nbsp;<a href="page54.html">54</a>&nbsp;&nbsp;&nbsp;<a href="page55.html">55</a>&nbsp;&nbsp;&nbsp;<a href="page56.html">56</a>&nbsp;&nbsp;&nbsp;<a href="page57.html">57</a>&nbsp;&nbsp;&nbsp;<a href="page58.html">58</a>&nbsp;&nbsp;&nbsp;<a href="page59.html">59</a>&nbsp;&nbsp;&nbsp;<a href="page60.html">60</a>&nbsp;&nbsp;&nbsp;<a href="page61.html">61</a>&nbsp;&nbsp;&nbsp;<a href="page62.html">62</a>&nbsp;&nbsp;&nbsp;<a href="page63.html">63</a>
             </td>
             <td width="35%"><a href="page59.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page59.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
